• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Methyltransferase Assay Kits
      • Ligase and Synthetase Assay Kits
      • Phosphodiesterase Assay Kits
    • HTS Assays by Target
      • AMPK Assay Kits
      • cGAS Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • TBK1 Assay Kits
    • Recombinant cGAS Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • GTPase Profiling Services
    • OAS1 Assay Services
  • Innate Immunity
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD39 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • OAS1 Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Application Notes
    • Transcreener® Assays – Instrument Compatibility
    • Posters and Presentations
    • Publications
    • Technical Manuals
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Tag: AptaFluor SAH Methyltransferase Assay

The Contribution of DNA Methyltransferase Inhibitors in Treating Myelodysplastic Syndromes

Tuesday, 01 October 2019 by Bellbrook Labs
DNA Methyltransferase Inhibitors for MDS
Myelodysplastic syndromes (MDS) are a broad, complex group of cancers characterized by the inability to form mature, healthy blood cells. There are different types with varying degrees of risk associated, making it difficult to diagnose and treat. Additionally, many patients are symptom-free and at an older age where they are likely to have other life-threatening
AptaFluor SAH Methyltransferase Assaydna methyltransferase inhibitors
Read more
  • Published in Emerging Targets, Epigenetics
No Comments

How a Methyltransferase Activity Assay Could Help Identify Novel Breast Cancer Treatments

Monday, 22 April 2019 by Bellbrook Labs
Pink Stethascope DOT1L Breast Cancer Target 420 X 280
As estrogen receptor (ER) positive breast cancer (BC) becomes resistant to antiestrogen therapy, novel ways to control the disease are and continue to be developed. There are different types of breast cancer, and the most effective treatment depends on knowing this difference.  For example, if the type is estrogen receptor positive (ER) meaning cells are
AptaFluor SAH Methyltransferase Assaymethyltransferase
Read more
  • Published in HTS Assays, Products
No Comments

Sensitive Methyltransferase Assay Proves Successful with PRMT4

Thursday, 11 October 2018 by Bellbrook Labs
Histone Methylation PRMT4
Histone methyltransferases (HMTs) play a critical role in many diseases. Dysregulation of histone methylation and the subsequent alterations in epigenetic states can cause gene expression patterns that drive a variety of cancers,[1] endometriosis,[2] osteoporosis,[3] osteoarthritis and rheumatoid arthritis,[4] cardiovascular disease,[5] and autism,[6] to name only a few. In this light, a global assay for HMT
AptaFluor SAH Methyltransferase Assaymethyltransferase
Read more
  • Published in Epigenetics, HTS Assays
No Comments

Visit With BellBrook Labs at Discovery On Target 2018

Tuesday, 04 September 2018 by Bellbrook Labs
Discovery on Target 2018
BellBrook Labs will exhibit and present posters at the upcoming Discovery on Target conference in Boston, MA. At the event BellBrook will demonstrate applications for its suite of high throughput screening tools, including residence time determination, methyltransferase activity measurement, studying ectonucleotidase enzymes, screening for kinase inhibitors, and more! Discovery on Target 2018 Sheraton Boston Hotel
AptaFluor SAH Methyltransferase AssayTranscreener ADP Kinase AssayTranscreener AMP/GMP Assay
Read more
  • Published in News
No Comments

A Novel Approach Discovers Hundreds of Cancer-Relevant Arginine Methylation Sites for CARM1

Thursday, 14 December 2017 by Bellbrook Labs
Protein arginine methylation is an important post-translational modification, but its impact remains rather mysterious. Approximately 7% of all arginine residues in the human proteome are modified by mono- or di-methylation (which is a similar order of magnitude to the 9% of serine residues that are phosphorylated and the 7% of lysine residues that are ubiquitinated).¹
AptaFluor SAH Methyltransferase AssayAssay Development Servicesdrug discovery servicesEPIGEN Methyltransferase Assaymethyltransferase
Read more
  • Published in Epigenetics, HTS Assays, Products, Uncategorized
No Comments

New Posters from DOT 2017

Friday, 29 September 2017 by Bellbrook Labs
Poster Presentations A Homogenous, High Throughput Assay to Measure Guanine Nucleotide Exchange Factor Activity Using Transcreener® GDP Assay Guanine nucleotide exchange factors (GEFs) positively regulate Rho GTPases by accelerating GDP dissociation to allow formation of the active, GTP-bound complex. Development of inhibitors that specifically disrupt GEF action on a target Rho GTPase may be a
AptaFluor SAH Methyltransferase AssayAssay Development Servicesdrug discovery servicesLead Discovery ServicesTranscreener AMP/GMP AssayTranscreener cGAMP cGAS AssayTranscreener GDP Assay
Read more
  • Published in HTS Assays, News
No Comments

BellBrook Labs Launches Ultra-Sensitive Methyltransferase Assay to Accelerate Epigenetic Drug Discovery

Thursday, 10 August 2017 by Bellbrook Labs
Methyltransferases have become a major focus of drug discovery for cancer and other diseases driven by epigenetic factors.  BellBrook Labs’ new, ultra-sensitive AptaFluor™ SAH Methyltransferase Assay eliminates cost and sensitivity barriers that are slowing the discovery of methyltransferase inhibitors. New AptaFluor SAH Methyltransferase Assay Schematic BellBrook Labs announces the launch of their latest drug discovery
AptaFluor SAH Methyltransferase AssayAssay Development ServicesepigeneticsLead Discovery Servicesmethyltransferase
Read more
  • Published in Epigenetics, News, Uncategorized
No Comments

Previously Recorded Webinar – The New AptaFluor™ SAH Methyltransferase Assay: A Homogenous, Universal Assay Based on a Microbial Riboswitch

Monday, 31 July 2017 by Bellbrook Labs
Epigenetic regulation has been shown to be a contributing factor in a variety of diseases, and discovery of methyltransferase inhibitors is an area of intense activity. Methyltransferase enzymes methylate a variety of substrates using S-adenosylmethionine (SAM) as the methyl donor leaving S-adenosylhomocysteine (SAH) as a common product. Since the difference between SAH and SAM is
AptaFluor SAH Methyltransferase Assayepigeneticsmethyltransferase
Read more
  • Published in Epigenetics, HTS Assays, Products
No Comments

EZH2 Methyltransferase Inhibitors Hold Promise for Combating Neuropathic Pain

Friday, 21 July 2017 by Bellbrook Labs
When people experience neuropathic pain, they often describe “pins and needles” sensations or burning, shooting, or stabbing pain that can be agonizing and difficult to bear. In some cases, neuropathic pain is so intense that the pressure of clothing or the weight of a bed sheet can cause misery. Chronic neuropathic pain can be caused
AptaFluor SAH Methyltransferase AssayAssay Development ServicesEPIGEN Methyltransferase AssayLead Discovery Servicesmethyltransferase
Read more
  • Published in Emerging Targets, Epigenetics, HTS Assays
No Comments

BellBrook Labs Awarded NIH Funding for Collaboration with University of Utah to Develop Biosensors for Epigenetic Drug Discovery

Monday, 12 December 2016 by Bellbrook Labs
BellBrook Labs was awarded a Phase I grant of $225,000 to develop biosensors for detection of chromatin modifying enzymes, such as acetyltransferases and methyltransferases, in collaboration with University of Utah chemist Jennifer Heemstra. The collaboration leverages nucleic aptamer technology being developed by Dr. Heemstra to streamline development of assays for epigenetic enzymes being targeted for
AptaFluor SAH Methyltransferase AssayAptamer
Read more
  • Published in Epigenetics, HTS Assays
No Comments
  • 1
  • 2
  • 3

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Researcher Using An ADP Assay

    Accelerating Discovery of Kinase Inhibitors Using an ADP Assay

    An ADP assay can be used to study the activity ...
  • Inhibitors of ENPP1 SLAS Discovery

    New Publication by the Scientists at BellBrook Labs – Development of a High-Throughput Assay to Identify Inhibitors of ENPP1

    BellBrook scientist Meera Kumar and Robert Lowe...
  • GMP Assay for PDE Inhibitor Discovery

    Using a Universal GMP Assay for PDE Research

    A universal GMP assay to aid in PDE research an...
  • SLAS 2021

    Join Us for SLAS 2021 Virtual Conference

    BellBrook Labs will be exhibiting at SLAS 2021,...
  • New cGAS TR-FRET Assay

    New TR-FRET Readout Now Available with the Transcreener cGAMP cGAS Assay

    Launched in November 2019, the Transcreener cGA...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2019 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP